NOV 4 2002

K023569 page 1 of 2

1. 510(k) SUMMARY

as required per 807.92(c)

Submitters Name, Address:

Siemens Medical Solutions, Inc. Electromedical Systems Group, PCS

Danvers, MA 01923 Tel: (978) 907-7500 Fax: (978) 750-6879

Establishment Registration Number: 1220063

Official Correspondent: Connie Hertel, Director, QA/RA Contact person for this submission: Penelope H. Greco Date submission was prepared: October 21, 2002

Trade Name, Common Name and Classification Name:

A. Trade Name:

INFINITY MultiView WorkStation

B. Common Name, Classification Name, Class and Regulation Number:

Common Name	Product	Class	Regulation
	Code		Number
Detector and Alarm, Arrhythmia	DSI	III	870.1025
System, Network and Communication,	MSX	II	870.2300
Physiological Monitors			

Legally Marketed Device Identification:

K955059 Olympus Communications Network, SC 3000 WorkStation and Remote Display (now referred to as the Infinity Network, MultiView WorkStation and Remote Display)

K003246 Infinity VentViewer (now known as VentCentral)


Device Description:

Introduction

Some features included in the Infinity MultiView WorkStation VF3 software release are locked options that will be submitted separately.

Page 1 of 2

Tel: (978) 907-7500 Fax: (978) 750-6879



The Infinity MultiView WorkStation (MVWS) software version VF3 modifications include:

Waveform Export

Waveform Export allows the user to export 25 hours of the four full disclosure waveforms to any client device. The export protocol uses Native File System (NFS), a standard file transfer protocol.

Calipers

The release of software version VF3 includes the caliper application, which is an extension of the Full Disclosure database application. The caliper application allows the user to select an 18-second ECG waveform segment from the Full Disclosure database and perform simple caliper measurements.

Selected Strip Report

The Selected Strip Report allows the user to select an area of the topmost channel within Full Disclosure by defining the beginning and ending cursor times.

Second SpO2 and Pulse Parameter Support

Minor software modifications have been implemented to support a second SpO2 and Pulse parameter received from the bedside.

The Indications for Use have not changed with the implementation of Waveform Export, Calipers, or support for a second SpO2 and Pulse parameter received from the bedside. Testing has been performed according to internal design control procedures and indicates no affect on the safety or efficacy of the MultiView WorkStation.

Intended Use:

The intended use of Siemens MultiView WorkStation & INFINITY Network is to act as a communications network, central monitoring device, and remote display for Siemens Patient Monitoring Systems and recorders.

Assessment of non-clinical performance data for equivalence: Section J

Assessment of clinical performance data for equivalence: Not applicable

Biocompatability: Not applicable

Sterilization: Not applicable

Standards and Guidances: Section E

Page 2 of 2

Siemens Medical Solutions, Inc.

Electromedical Systems Group, PCS

16 Electronics Avenue Danvers, MA 01923

Tel: (978) 907-7500 Fax: (978) 750-6879



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

NOV 4 2002

Siemens Medical Solutions, Inc. c/o Ms. Penelope H. Greco Regulatory Submissions Manager Electromedical Systems Group, PCS 16 Electronics Avenue Danvers, MA 01923

Re: K023569

Trade Name: INFINITY MultiView WorkStation

Regulation Number: 21 CFR 870.1025

Regulation Name: Arrhythmia Detector and Alarm

Regulatory Class: Class III (three)

Product Code: MHX
Dated: October 21, 2002
Received: October 24, 2002

Dear Ms. Greco:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 – Ms. Penelope H. Greco

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

				Koz	3569		
			Page_1_of_1				
510(k) Number (if known): <u>50233</u>	69	•					
Device Name: <u>INFINITY MultiView</u>	WorkStation						
Indications for Use:							
Siemens Infinity MultiView Wo are indicated for use as a central remote display for Siemens Patien	monitoring device	e, communic	ations network				
•		•	. ·	et.	e de la companya de l		
MRI Compatibility Statement: The MultiView WorkStation and Infinity No.	ctwork are not compa	atible for use in	a MRI magnetic	field.			
(PLEASE DO NOT WRITE BELOW NEEDED)	THIS LINE-CONT	ΓINUE ON AÌ	NOTHER PAGE	E IF			
Concurrence of CDR	H, Office of Device	ee Evaluation ((ODE)	_			
Prescription Use	OR	Over-T	he-Counter Use				
(Per 21 CFR 801.109)			Optional Forma				
Division of Cardiovascula 510(k) Number	r & Respiratory Devic	es —					